Handelsavisen
prelaunch
Companies ›Consumer Non Cyclicals ›300957.SZ
30
300957.SZ — Shenzhen Stock Exchange Personal Products

Yunnan Botanee Bio-Technology Group Co Ltd

¥37,99
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
16,1B CNY
P/E
—
EV / Rev
—
Div yield
1,10 %
Op margin
11,7 %
ROE
8,2 %
Net margin
9,4 %
Debt / equity
0,14
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Yunnan Botanee Bio-Technology Group Co Ltd is a personal products company that develops, produces, and sells health and beauty products, primarily in the Chinese market.

Business. Yunnan Botanee Bio-Technology Group Co Ltd (300957.SZ) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorPersonal & Household Products & Services
IndustryPersonal Products
Generated · model-assisted
Sell-side consensus
BUY15 analysts
8 buy6 hold1 sell
Avg 12m price target44,51

Analyst recommendations

15 analysts · consensus Buy
Buy8
Hold6
Sell1
12-month price target
44,51
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
15 analysts · indicative
Ownership
—
not yet wired
Profitability→
8,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300957.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300957.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Yunnan Botanee Bio-Technology Group Co Ltd (300957.SZ) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorPersonal & Household Products & Services
    IndustryPersonal Products
    AI synthesis
    GENERATED

    Yunnan Botanee Bio-Technology Group Co Ltd has a market price of 37.87 CNY and a market capitalization of 16,041,732,000 CNY, with a price-to-earnings ratio of 31.72 and a price-to-book ratio of 2.61. The company's equity is valued at 6,157,265,030 CNY, and its total liabilities amount to 2,184,081,860 CNY, resulting in a debt-to-equity ratio of 0.14. The company's liquidity is assessed as medium, with a current ratio of 3.77, but it has negative net cash after subtracting total debt.

    The company's profitability is reflected in a return on equity of 8.21% and a return on assets of 6.06%. Its operating income of 628,929,380 CNY and net income of 505,719,670 CNY indicate a healthy margin, although the free cash flow is negative at -16,435,960 CNY. The company's capital expenditure of -482,989,260 CNY suggests significant investment in its operations.

    Yunnan Botanee Bio-Technology Group Co Ltd operates primarily in the Chinese market, with no disclosed segment or geographic breakdown provided in the available data. The company's revenue concentration is not specified, but its business model is centered around personal care products, which are typically less sensitive to macroeconomic fluctuations.

    The company's revenue for the latest period is 5,358,638,780 CNY, and its outlook for the current fiscal year is not explicitly provided. Analysts have a mean price target of 44.51 CNY, with a median of 44.00 CNY, indicating a potential upside from the current market price. The company's growth trajectory is supported by its operating cash flow of 976,595,740 CNY, which suggests strong operational performance.

    The company's risk assessment indicates a low dilution risk, with no near-term pressure for additional share issuance. However, the negative free cash flow and significant capital expenditure may pose liquidity challenges in the short term. The company's liquidity risk is moderate, and its credit risk is not explicitly detailed in the available data.

    Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. Analysts have issued a mean recommendation of 2.27, with 4 strong-buy, 4 buy, and 6 hold ratings, indicating a generally positive outlook.

    Key takeaways
    • Yunnan Botanee Bio-Technology Group Co Ltd has a strong return on equity of 8.21% and a healthy operating income of 628,929,380 CNY.
    • The company's market price of 37.87 CNY is below the mean analyst price target of 44.51 CNY, suggesting potential upside.
    • The company's liquidity is assessed as medium, with a current ratio of 3.77, but it has negative net cash after subtracting total debt.
    • Analysts have issued a generally positive outlook, with 4 strong-buy and 4 buy ratings.
    • The company's capital expenditure of -482,989,260 CNY indicates significant investment in its operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥37,99
    Market cap
    ¥16.04B
    Enterprise valueⓘ
    ¥16.88B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    17.3x
    P / Bⓘ
    2.6x
    P / Tangible bookⓘ
    2.6x
    Tangible book
    ¥6.16B
    Net cashⓘ
    -¥834.2M
    Current ratioⓘ
    3.8
    Debt / equityⓘ
    0.1
    ROAⓘ
    6.1%
    ROEⓘ
    8.2%
    Cash conversionⓘ
    193.0%
    CapEx / revenueⓘ
    -9.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,45
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    15
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate1,45
    Revenue—no estimate—no estimate6,0B CNY
    Operating income—no estimate—no estimate662,6M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution15 analysts
    Strong buy4
    Buy4
    Hold6
    Sell1
    Strong sell0
    12-month price target¥44,51 · Median ¥44,00
    Low ¥34,50High ¥53,64
    Operating income · consensus662,6M CNY
    EPS surprise
    −17,4 %
    reported vs consensus · miss
    Revenue surprise
    −11,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥34,50
    Mean¥44,51
    Median¥44,00
    High¥53,64
    Spot¥37,99
    +17.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin11,7 %Above median
    Net Margin9,4 %Above median
    ROE8,2 %Above median
    Capex / Rev-9,0 %Bottom quartile
    D/E0,14Below median
    Cash Conv1,93Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Yunnan Botanee Bio-Technology Group Co Ltd Market data — financials · 2026-05-26
    • Yunnan Botanee Bio-Technology Group Co Ltd Market data — analyst estimates · 2026-05-26
    • Yunnan Botanee Bio-Technology Group Co Ltd Market data — ESG · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300957.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage